Osteoboost Health Inc. today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 12,232,993 for Osteoboost, the first FDA-cleared wearable device designed to treat osteopenia and improve bone health through targeted vibration therapy, and the only non-drug prescription treatment for bone density cleared by the FDA.
This is Osteoboost’s 6th patent in the US. It is expected to launch in Q2 2025.
Titled “Wearable Apparatus for the Treatment or Prevention of Osteopenia and Osteoporosis, Stimulating Bone Growth, Preserving or Improving Bone Mineral Density, and Inhibiting Adipogenesis,” this newly issued patent further strengthens BHT’s intellectual property portfolio. The patent covers key innovations, including:
- A wearable vibrating apparatus that delivers mechanical stimulation to bones, helping preserve and improve bone density.
- Integrated accelerometers to monitor treatment effectiveness and ensure compliance.
- Advanced tracking and reminder features for personalized bone health management.
Osteoboost incorporates key innovative and patented features specifically designed to optimize the bone-strengthening impact of the treatment on the hips and spine. Uniquely, Osteoboost has two embedded sensors that calibrate the vibration dose at the beginning of each treatment session ensuring that every treatment session provides a therapeutic dose of vibration to the patient. In addition, the frequency and magnitude of the vibration are optimized for building bone.
As a result of these core features, Osteoboost is the only medical device cleared by the FDA as safe and effective for the treatment of low bone density
"Osteoboost is pioneering a new standard of care for individuals at risk of osteoporosis,” said Laura Yecies, CEO of Osteoboost Health, Inc. “This patent underscores our commitment to innovation and validates the groundbreaking technology behind Osteoboost. By providing a non-drug solution backed by clinical research, we will empower millions of people with osteopenia to take control of their bone health.”
Osteoboost is FDA-cleared and clinically proven to reduce bone loss through a proprietary vibration therapy that stimulates bone growth. It offers a convenient, at-home solution for those looking to maintain or improve their bone density without medication.
The company also announced today its name is changing from Bone Health Technologies to Osteoboost Health, Inc. to streamline corporate and product branding.
About Osteoboost Health, Inc.
Osteoboost Health is a Redwood City-based medical technology company developing innovative, non-invasive, and science-backed solutions for people with low bone density. Its flagship product, Osteoboost, is an FDA-cleared wearable medical device clinically proven to significantly slow the loss of bone density and bone strength through patented precision vibration therapy in postmenopausal women with osteopenia.
Inspired by NASA-funded research and driven by science and a commitment to improving health outcomes, Osteoboost is poised to become the new standard of care – offering a convenient, non-pharmacological, pain-free treatment to the nearly 64 million Americans at risk of osteoporotic fractures.
Osteoboost is backed by leading investors, including Esplanade Ventures, Terumo Medical Corporation, Ambit Health Ventures, Portfolia, Astia Angels, and Golden Seeds. For more information about BHT and Osteoboost, including the Instructions for Use, please visit https://osteoboost.com/.